Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Novo Nordisk A/S — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $37.17 (market cap $119.10M), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 1388× Roundhill NVDA WeeklyPay ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill NVDA WeeklyPay ETF for 50 Days and Novo Nordisk A/S for 116 Days on average.
| NVDW | NVO | |
|---|---|---|
Market Cap | $119.10M | $165.31B |
Volume | 44,838 | 11,432,838 |
Sector | Income / Options Overlay | Health |
52-Week High | $52.33 | $63.98 |
52-Week Low | $31.88 | $35.29 |
Typical Hold Time | 50 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $37.11, down 4.11% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF provides weekly dividend income tied to Nvidia's performance with 120% leveraged exposure. Recent Nvidia earnings beat expectations, supporting the AI theme's momentum, though the fund carries elevated risk due to leverage and NAV volatility during Nvidia downturns.
The outlook remains tied to Nvidia's AI-driven growth, offering high-yield income potential but with significant volatility risk. Investors face exposure to Nvidia's stock performance amplified by leverage, making the fund suitable for risk-tolerant income seekers but vulnerable to sharp corrections in the underlying asset.
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
